NYSE:NAVB
Delisted

Navidea Biopharmaceuticals Stock News

etoro logo Buy NAVB
*Your capital is at risk
$0.0001
+0 (+0%)
At Close: Dec 30, 2025
Investors need to pay close attention to Navidea Biopharmaceuticals (NAVB) stock based on the movements in the options market lately.
Maxim Group analyst Jason McCarthy assigned a Buy rating to Navidea (NAVB – Research Report) today and set a price
Retail sales surging 18% in May fared well with the markets this morning, but with growing concerns over a Coronavirus resurgence, it's clear that volatility is just around the corner. We've utilized
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is please
DUBLIN, Ohio, June 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development
DUBLIN, Ohio, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development

Company News for May 26, 2020

02:11pm, Tuesday, 26'th May 2020
Companies In The News Are: TTWO, XERS, SPLK, NAVB

71 Biggest Movers From Friday

08:30am, Tuesday, 26'th May 2020
U.S. stock benchmarks end up for the week despite rising Sino-American tensions and a holiday that could test the bounds of business reopening efforts after...
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE